FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL					
OMB Number:	3235-0287				
stimated average burden					
ours per response	0.5				

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Danas	·tina O	wners														
Stock Option	<u>(1)</u>	02/07/2019		A		1,000,0	00	<u>(1</u>	0	2/07/2029	Common	1,000,000	\$ 0	2,065,000	D	
				Code	V	(A)	(D)	Date Exercis		Expiration Date	Title	Amount or Number of Shares		Transaction(s (Instr. 4)	(Instr. 4)	
	Conversion	Date (Month/Day/Year) a	Execution Date, if	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5))		te		g Securities nd 4)		f 9. Number of Derivative Securities Beneficially Owned Following Reported	Ownership Form of Derivative Security: Direct (D) or Indirect	Benefici Ownersh (Instr. 4)
Reminder:	Report on a	separate line for eac		- Deriv	ative	Securitie	es Acqu	Pers in th a cu iired, Di	ons wis form		equired to B control	o respond u number.		on containe form displa		174 (9-02)
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Yea	r) any	utior	ned n Date, if Day/Year)			(A) (or Disposed or 3, 4 and 5 (A) or (D)	of (D) Ov Tr	Amount of Se wned Followin ansaction(s) astr. 3 and 4)		O F D o: (I	wnership of orm: B irect (D) Or Indirect (I	eneficial wnership
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui												
(Street) DUBLIN, OH 43017			4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(Last) (First) (Middle) 4995 BRADENTON AVE., SUITE 240			3. Date of Earliest Transaction (Month/Day/Year) 02/07/2019							CEO, COO & CFO						
(Print or Type Responses) 1. Name and Address of Reporting Person * Latkin Jed				2. Issuer Name and Ticker or Trading Symbol NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director					

Describes Occurs Name / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Latkin Jed 4995 BRADENTON AVE., SUITE 240 DUBLIN, OH 43017	X		CEO, COO & CFO			

Signatures

/s/ Jed A. Latkin	02/11/2019
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- 333,334 options with a strike price of \$0.15 will be exercisable on or after 2/7/2019, so long as the closing market price of the underlying common stock equals or exceeds \$0.50 per share;
 333,333 options with a strike price of \$0.30 will be exercisable on or after 12/31/2019, so long as the closing market price of the underlying common stock equals or exceeds \$0.70 per share; and 333,333 options with a strike price of \$0.50 will be exercisable on or after 12/31/2020, so long as the closing market price of the underlying common stock equals or exceeds \$1.00 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.